Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Sarcoma 1Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1Acrocephalosyndactylia 1

Interventions

Gemcitabine 2ruxolitinib 1rucaparib 1pemigatinib 1pembrolizumab 1motexafin gadolinium 1abiraterone 1Watchful Waiting 1Vorinostat 1Trastuzumab 1Tinzaparin 1TTI-621 1Rituximab 1Paclitaxel 1Nivolumab 1Ipilimumab 1In Situ Hybridization, Fluorescence 1INCB057643 1Fentanyl 1Epoetin Alfa 1Doxorubicin 1Docetaxel 1Cisplatin 1CTLA-4 Antigen 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × pemigatinib × Thoracic × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡